Form 4: Orchestra BioMed Officer's Routine Stock Withholding
Insider Transaction Report
Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, engaged in a routine transaction involving the withholding of 203 shares of common stock to satisfy tax obligations related to restricted stock unit vesting.
Summary
- Joshua Aiello, Principal Accounting Officer of Orchestra BioMed Holdings, Inc. (OBIO), reported a transaction on September 17, 2025.
- The transaction involved the disposition of 203 shares of Common Stock, par value $0.0001 per share, at a deemed price of $2.46 per share.
- This disposition was a withholding by the Issuer to satisfy tax obligations associated with the vesting of restricted stock units.
- No shares were sold in the open market as a result of this vesting and tax satisfaction.
- Following this transaction, Mr. Aiello beneficially owns 19,126 shares of Common Stock.
Sentiment
Score: 5
Explanation: The transaction is a routine, non-discretionary event related to tax withholding for restricted stock unit vesting, indicating a neutral impact on company sentiment.
Future Outlook
NA
Industry Context
This Form 4 reports a routine insider transaction related to compensation and tax obligations, which typically does not have broader industry implications or competitive relevance.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.
- No direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 09/17/2025 | Date of earliest transaction (withholding of shares for tax obligations) |
| 09/19/2025 | Date Form 4 was signed by reporting person's attorney-in-fact |
Recommendation
holdThis Form 4 details a routine, non-discretionary transaction where shares were withheld to cover tax obligations arising from restricted stock unit vesting. It does not reflect a discretionary sale by the officer, nor does it provide new information about the company's operational performance, financial health, or strategic direction. Therefore, it offers no basis to change an existing investment thesis, warranting a 'hold' recommendation.
Keywords
Orchestra BioMed, OBIO, Joshua Aiello, Form 4, Insider Transaction, Stock Withholding, Restricted Stock Units, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.